Physician profile
Victoria Moss
NPI 1679718027
$472,784.82
in general payments reported to CMS, 2019-2025
29 companies · $58K in 2025
The $58K reported for 2025 was more than what 97% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48K · 2020: $19K · 2021: $39K · 2022: $95K · 2023: $127K · 2024: $87K · 2025: $58K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $242K · Travel and Lodging: $23K · Food and Beverage: $6,331 · Education: $99.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $242,042.64 |
| Travel and Lodging | $23,273.74 |
| Food and Beverage | $6,331.43 |
| Education | $99.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $270,736.39 | 2019-2025 | |
| Allergan, INC. | $197,779.04 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $737.80 | 2019-2023 | |
| Janssen Biotech, INC. | $512.18 | 2019-2024 | Tremfya, Stelara, Simponi Aria |
| Sun Pharmaceutical Industries INC. | $450.40 | 2019-2024 | Ilumya, Winlevi, Absorica Ld |
| Lilly USA, LLC | $395.93 | 2019-2024 | Taltz, Olumiant |
| Regeneron Healthcare Solutions, INC. | $228.62 | 2019-2024 | Dupixent, Libtayo |
| Incyte Corporation | $222.96 | 2022-2024 | Opzelura |
| Amgen INC. | $205.34 | 2020-2024 | Otezla |
| Janssen Scientific Affairs, LLC | $166.26 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $151.44 | 2022-2024 | Sotyktu |
| Pfizer INC. | $151.17 | 2019-2024 | |
| Genzyme Corporation | $150.62 | 2019-2024 | |
| Strata Skin Sciences, INC. | $147.76 | 2022-2023 | Xtrac |
| Ucb, INC. | $123.25 | 2019-2024 | Bimzelx |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $96.52 | 2019-2022 | |
| Vyne Pharmaceuticals INC. | $88.55 | 2020 | |
| Celgene Corporation | $63.62 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.21 | 2023 | Cyltezo, Spevigo |
| Leo Pharma INC. | $50.91 | 2020-2022 | |
| Medtronic, INC. | $49.59 | 2022 | |
| Organogenesis INC. | $48.25 | 2021-2023 | Puraply |
| Galderma Laboratories, L.P. | $43.57 | 2020-2023 | Oracea, Aklief, Epsolay |
| Prugen, INC. Pharmaceuticals | $33.45 | 2019 | |
| Merz North America, INC. | $25.72 | 2025 | |
| Mayne Pharma Commercial LLC | $25.22 | 2022 | |
| Dermira, INC. | $17.11 | 2020 | |
| Dermavant Sciences, INC. | $16.84 | 2023 | Vtama |
| Mission Pharmacal Company | $14.10 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victoria Moss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.